

12 August 2024

Life Science REIT plc
("Life Science REIT" or the "Company")

Notice of Half Year Results

Life Science REIT (LSE: LABS), the real estate investment trust focused on UK life science properties, will announce its half year results for the six months ended 30 June 2024 on Thursday, 26 September 2024.

There will be an in-person presentation for analysts and professional investors at 9am on the morning of the results announcement, as well as a live audio webcast. Please contact FTI Consulting for further details or to register interest. A recording of the session will be made available to all investors to follow.

-ENDS-

Enquiries:

Ironstone Asset Management - Investment Adviser +44 20 3011 2160
Simon Farnsworth, Managing Director
Simon.farnsworth@ironstoneam.com
Joanna Waddingham, Head of Investor Relations and Corporate Affairs
Joanna.Waddingham@ironstoneam.com

Link Company Matters Limited - Company Secretary
labs_cosec@linkgroup.co.uk

Panmure Liberum Limited - Joint Corporate Broker +44 20 7886 2500
Alex Collins / Tom Scrivens

Jefferies International Limited - Joint Corporate Broker +44 20 7029 8000
Tom Yeadon / Oliver Nott

G10 Capital Limited - AIFM +44 20 7397 5450
Maria Baldwin

FTI Consulting - Financial PR & IR Adviser +44 20 3727 1000
Dido Laurimore / Richard Gotla / Oliver Parsons
LifeScienceReit@fticonsulting.com

Notes to editors

Life Science REIT plc is a specialist property business focused on the UK's growing life science sector. The Company's portfolio of assets is located across the "Golden Triangle" of research and development hubs in Oxford, Cambridge and London's Knowledge Quarter and its strategic vision is to become the property provider of choice for life science companies in the UK.

Life Science REIT is addressing the acute demand-supply imbalance for laboratory space in the "Golden Triangle", which is characterised by low vacancy rates and prime rental increases. The UK life science sector itself is underpinned by strong structural drivers, including an ageing population and a supportive regulatory environment as well as the growing interdependence with technology, which is expanding the life science spectrum, driving strong demand for laboratory space.

The Company's diverse portfolio of assets ranges from a 20-acre science park currently under development through to fully let buildings, with an important part of the Company's strategy being the conversion of existing properties to laboratory space.

The Company's investment policy is focused on capital growth whilst also providing a growing level of income.

Life Science REIT trades on the Main Market of the London Stock Exchange under the ticker LABS.

Further information is available at <https://lifesciencereit.co.uk>. To sign up for email alerts, please visit <https://lifesciencereit.co.uk/investors/>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORFLFSETVIAIIS